The Diary Of A CEO
GLP-1 weight-loss drugs effectively suppress appetite and addiction cravings, but users face severe physical risks and high weight-regain rates without systemic food industry reform.
AI-assisted summary of Johann Hari: They’re Lying To You About The Side Effects Of Ozempic! — original source. Check the original for full context.
Source published:
Detailed notes
## Background This episode of The Diary Of A CEO was published on YouTube by Steven Bartlett on April 29, 2024. The page description introduces New York Times best-selling author Johann Hari and highlights his book, 'Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs', while framing a discussion on the hidden side effects, benefits, and societal impacts of Ozempic.
## TL;DR Author Johann Hari discusses the transformative impact and potential hidden risks of GLP-1 weight-loss drugs like Ozempic, drawing from his personal experience losing 42 pounds and extensive global research. The conversation explores how these medications suppress appetite by altering brain signals, their potential to treat addictions beyond food, and the significant risks of muscle loss, pancreatitis, and long-term unknown side effects. Hari and Bartlett debate whether GLP-1s serve as a necessary tool against an obesogenic food environment engineered by the food industry or a systemic shortcut masking deeper societal issues.
## Atmosphere & style The dialogue feels deeply intimate, candid, and intellectually curious, driven by Hari's expressive storytelling and Bartlett's probing, reflective host style. The conversation shifts fluidly from personal vulnerability regarding body image and cultural shame to rigorous scientific scrutiny and sobering historical warnings. Throughout the episode, there is an underlying sense of moral urgency and existential contemplation about health, human nature, and societal food systems.
## Key takeaways - [00:00](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=0s) GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro deliver unprecedented weight loss results (averaging 15% to 24%), whereas traditional dieting long-term success rates hover around only 10%. - [00:00](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=0s) Discontinuing GLP-1 medications typically results in regaining approximately 70% of the lost body weight within a single year. - [06:51](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=411s) Synthetic GLP-1 agonists mimic natural gut hormones but linger in the body for a week rather than minutes, significantly suppressing appetite and altering brain reward centers. - [20:12](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1212s) The 'Cheesecake Park' experiment demonstrates how ultra-processed foods hijack mammalian biology, triggering compulsive overeating that overrides normal satiety and survival instincts. - [52:25](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3145s) Rising global obesity is largely driven by an 'obesogenic environment' engineered by ultra-processed food manufacturers, rather than a sudden collective failure of willpower. - [42:41](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2561s) Removing food as a primary emotional coping mechanism can unmask underlying psychological distress and trauma, leading to phenomenon like addiction transfer. - [01:07:43](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4063s) Taking GLP-1 drugs for five years reduces the risk of heart attacks and strokes by 20% in individuals with a BMI over 27. - [01:18:08](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4688s) Significant documented risks of GLP-1 drugs include rapid loss of lean muscle mass (sarcopenia), acute pancreatitis, gallstones, gastrointestinal distress, and elevated relative risks of thyroid cancer. - [02:05:37](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7537s) Emerging clinical and animal research suggests GLP-1 agonists boost overall self-control and substantially diminish cravings for alcohol, opioids, and nicotine. - [01:43:26](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=6206s) Structural public health reforms—such as Japan's Metabo Law and strict food environment regulations—offer proven population-level solutions to obesity beyond individual medication.
## Detailed walkthrough ### [00:00](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=0s) Introduction and the Promise and Risks of Ozempic
The conversation opens with host Stephen Bartlett noting that guest Johann Hari looks remarkably different since they last spoke two years ago. Hari reveals that he lost three stone (roughly 42 pounds) in a single year, introducing the central topic: the revolutionary and controversial weight loss drug Ozempic. As a bestselling author using his own body to test these new treatments, Hari highlights how Ozempic has quickly become "literally the hottest drug in the country right now," promising massive benefits while carrying profound, often unexamined risks.
Hari points out that after 40 years of relentlessly promoting diet and exercise—where only about 10% of people successfully achieve major, long-term weight loss—society has suddenly produced "the most effective tool for self-starvation human beings have ever come up with." However, he cautions that these medications act directly on key areas of the brain and bring at least 12 significant risks that have not been adequately explained to the public.
* On average, users of Ozempic and Wegovy lose 15% of their body weight in a year, while next-generation GLP-1 drugs approach a 24% weight loss, rivaling bariatric surgery. * Users who discontinue the drug regain roughly 70% of their lost weight within a year. * Potential side effects and risks include severe muscular loss, acute pancreatitis, gallstones, gastrointestinal issues, and concerns regarding suicidal ideation.
---
[01:58](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=118s) The Hollywood Party Realization
Hari shares the origins of his personal experience with Ozempic, tracing it back to the winter of 2020 as post-pandemic gathering restrictions began to lift. Having gained significant weight during lockdown like many others, Hari attended a party hosted by a famous Hollywood actor. He anticipated that the celebrity attendees would have also put on weight, but instead arrived to a striking scene: guests appeared gaunt, clean-cut, and unusually sharp, looking "like their own Snapchat filter" with high cheekbones and lean frames.
Confused, Hari joked to a friend on the dance floor that everyone must have been practicing intensive Pilates during lockdown. She laughed and pulled out her phone to show him an image of an Ozempic pen, explaining that everyone from A-list stars to their agents, spouses, and kids was taking it. This revelation plunged Hari into deep internal conflict. Knowing his family history—his grandfather and uncle died young from heart attacks, and obesity is linked to over 200 health conditions—he recognized the immense medical appeal, yet remained deeply suspicious of yet another "miracle" diet drug and concerned about its impact on eating disorders and body positivity.
* Hari traveled globally for over a year—visiting experts in Reykjavík, Minneapolis, and Tokyo—to investigate the drug for his book *Magic Pill*. * Over 200 medical complications and diseases are directly linked to obesity. * Historical diet medications frequently promised dramatic short-term results before being pulled due to dangerous side effects.
---
[06:37](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=397s) Using the Pen, Costs, and How Ozempic Suppresses Appetite
Demonstrating an empty injection pen that resembles a large Sharpie, Hari explains the mechanics of administering the drug once a week via a tiny attachable needle. Recalling his very first dose, Hari describes waking up two days later with a mild background nausea and a strange realization: for the first time in his memory, he was not waking up ravenously hungry. Visiting his local cafe, he took just three bites of his usual chicken and mayo roll before feeling completely full, leaving the cafe worker asking if he was ill. A similar pattern played out at lunch, with Hari feeling "literally 80% less hungry than I normally am."
Hari clarifies that GLP-1 is a naturally occurring gut hormone released when eating to tell the brain "you've had enough stop eating," but natural GLP-1 clears out within minutes. Ozempic injects a synthetic version designed to remain active in the body for an entire week. While it slows gastric emptying in the gut, leading neuroscientists now emphasize that its main mechanism is acting directly on the brain to change appetite and food desires entirely.
* Each pen typically contains four doses, administered once per week. * In the UK, private prescriptions cost around £250 per month, whereas in the US, prices range between $800 and $1,200 per month depending on supply shortages. * Diabetics have used GLP-1 receptor agonists safely under medical licensing for roughly 18 years, though widespread use for obesity is far more recent. * Hari reduced his daily intake from approximately 3,200 calories to 1,800 calories after starting the medication.
---
[13:27](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=807s) Pleasure, Psychological Ties to Food, and the "Stuffing" Instinct
Addressing a major criticism of weight loss drugs, Bartlett asks whether losing the desire to eat robs people of day-to-day happiness. Hari acknowledges that for many, losing food pleasure is a massive drawback. He cites Danish scientist Jens Juul Holst—one of the key developers of GLP-1 drugs—who noted that a life without food pleasure is unbearable for many, leading them to quit the drug after a couple of years. Renowned UK food critic Jay Rayner similarly described visiting top Paris restaurants on the medication and finding the experience completely drained of enjoyment.
Hari notes, however, that his own psychological response was different. Taking the drug forced him to confront his underlying emotional relationship with food. Growing up in a turbulent environment, Hari had learned early in life to use heavy eating to self-soothe through "stuffing"—deliberately eating far past fullness until feeling physical pressure on the esophagus and stomach. Because attempting to stuff oneself on Ozempic causes violent nausea or vomiting, the drug forcibly broke that emotional coping mechanism, ultimately allowing him to eat slower and appreciate the taste of food more.
Here is a detailed, faithful walkthrough covering the provided section of the interview.
---
[15:43](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=943s) Social Eating Dynamics and the Three Theories of Brain Impact
Johann Hari describes how his friends noticed a marked shift in his eating behavior a few months after he started taking Ozempic. They pointed out that while eating with him used to feel stressful because he wolfed down his food without seemingly enjoying it, he now appeared to genuinely savor his meals. However, Hari stresses that he is atypical in this regard, noting that far more people experience the loss of food pleasure akin to food critic Jay Rayner.
Transitioning into how Ozempic affects the brain, Hari notes that while GLP-1 is produced in the gut to promote satiety, scientific research reveals it also interacts deeply with the brain. Discovered in the 1990s at Hammersmith Hospital in London, GLP-1 receptors exist throughout the human brain (and GLP-1 can even be produced in the brain and thyroid). Tagging the drug with dye in animal experiments demonstrates that it diffuses everywhere across the brain, meaning its primary impact is neurological. Hari shares a personal anecdote illustrating this shift: taking his godsons to McDonald's a week after starting the drug, he found himself completely unmotivated to order anything, prompting his godson to ask, "Who are you and what have you done with Johann?" He reflects on a rock-bottom moment on Christmas Eve 2009 at a local KFC where the staff presented him with a massive, signed Christmas card thanking their "best customer"—a horrifying realization given that it wasn't even the branch he frequented most.
According to neuroscientists Hari interviewed, there are three main competing theories regarding how GLP-1 receptor agonists impact the brain:
* **Dampening the Reward System:** The drug dampens the brain's reward centers (which govern pleasure from sex, food, and socializing). While this stops cravings for junk food, it raises serious concerns about whether it also dulls pleasure for passions like reading or writing, potentially triggering depression or suicidal ideation—prompting warnings required by the US FDA. * **Resetting Preferences:** Researchers like Dr. Carel le Roux and Dr. Adalia G. suggest the drug does not cause generalized depression or dullness, but rather resets taste preferences back to "factory settings," automatically steering individuals toward healthier foods. * **Boosting the Satiety System:** Professor Paul Kenny argues the brain possesses a dedicated satiety system alongside the reward system. Instead of turning down the reward system, GLP-1 drugs dial up the satiety system—the signal that tells a person they have had enough.
---
[20:12](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1212s) The "Cheesecake Park" Experiment and Food Addiction
Host Stephen Bartlett interjects with a personal observation, noting how sugar acts addictively in his own life—consuming a cookie one day creates a "sugar spiral" that drives intense cravings the next. He asks whether the reduced desire for junk food is simply a result of breaking the physical cycle of sugar consumption. Hari responds by referencing a pivotal animal study conducted by Professor Paul Kenny, Head of Neuroscience at Mount Sinai in New York, which Hari dubs the "Cheesecake Park" experiment.
Raised in Dublin, Kenny noticed upon moving to San Diego in his twenties that Americans ate drastically more sugar and fat than Irish people, causing him to gain 23 pounds (a stone and a half) within a year. To test whether processed foods fundamentally alter brain chemistry to compel overeating, Kenny designed an experiment with laboratory rats:
* **Baseline Diet:** When rats were provided an unlimited supply of their natural, evolutionarily adapted food pellets, they ate only until their hunger was satisfied and maintained stable weights with inherent "nutritional wisdom." * **Introduction of Processed Foods:** When introduced to an American diet featuring fried bacon, Snickers bars, and cheesecake, the rats abandoned their standard food entirely. They obsessively gorged on cheesecake, hurling themselves into it and emerging covered in it. Within days, their health indicators plummeted, and they became severely obese. * **Withdrawal and Starvation:** When Kenny removed the junk food and returned exclusively to the natural pellets, the rats refused to eat the natural food altogether—behaving as if it were no longer edible. They starved themselves until extreme hunger eventually forced them to consume it.
---
[26:17](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1577s) Compulsive Overeating and the "House on Fire" Analogy
Bartlett highlights a further stage of Kenny's experiment detailed in Chapter 2 of Hari's book: researchers conditioned the rats to associate a yellow light with an electric shock. When the light flashed while rats ate standard pellets, they ran away. However, when the yellow light flashed while they were eating cheesecake, the rats ignored the shock and continued eating. This proved that prolonged exposure to hyper-palatable foods creates a drive so intense that individuals will ignore severe negative consequences to consume it—a reality Hari recognized in his own past KFC addiction.
Hari explains that modern ultra-processed diets break the human body's natural satiety signals. Weight loss drugs like Ozempic or Mounjaro function by restoring these missing GLP-1 satiety hormones, offering what Professor Michael Lowe at Drexel University terms "an artificial solution to an artificial problem."
Addressing the ethical dilemma of using a drug rather than fixing the broken food system, Hari shares a conversation with his close friend ("Judy"), a single mother and breast cancer survivor:
> "When I had cancer, we know there is something in the environment that is triggering breast cancer in women... But you didn't say to me when I got breast cancer, 'Well, fuck me, all this environmental problem has caused this breast cancer and now you want to inject yourself with another poison, chemotherapy, in order to deal with it?' No, you said, 'Okay, we've got an environmental problem, obviously that environmental problem needs to be dealt with, but you've got to stay alive or you can't deal with it.'"
Judy offered a vivid analogy: if your house is on fire, you should certainly support building future homes out of non-flammable materials and mandating sprinklers, but your immediate priority must be to put out the fire in your own house. Hari connects this to real-world patients, citing Jeff Parker, a 66-year-old lighting designer in San Francisco weighing 16 stone, who turned to Mounjaro to save his life amidst severe heart, liver, and kidney complications.
* Global obesity rates have trebled in Hari's lifetime (since 1979). * In 1979, 6% of British people were obese, compared to 26% today. * Currently, 47% of Americans express a desire to take weight-loss medication. * Breast cancer affects 1 in 7 women in Britain and the US, compared to only 1 in 38 women in Japan, pointing to environmental triggers.
[30:43](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1843s) Environmental Causes vs. Individual Survival
Johann Hari begins by reflecting on a conversation with a friend named Jeff who lost a significant amount of weight on GLP-1 medication. Jeff's health problems completely reversed, and he went from suffering to walking his dog across the Golden Gate Bridge every day in a happy retirement. When Hari asked Jeff if society shouldn't instead focus on fixing the root environmental causes of obesity, Jeff agreed in principle but offered a pragmatic counter argument: while he supported systemic campaigns, he would be dead long before society fixed the food environment, and he wanted to live now. Hari admits finding that logic difficult to dispute.
When challenged with the common societal critique—"Why not just make better choices at the coffee shop and choose a salad?"—Hari confesses that this was the exact self-critical voice inside his own head. He recalls another dinner conversation with a friend where Hari was weighing the risks of obesity against the risks of GLP-1 medications.
- When Hari mentioned the 12 significant health risks associated with the new weight-loss drugs, his friend cut him off, arguing there was a third option: going on a diet and exercising, something Hari had successfully done in the past. - This internal and external pressure made Hari feel like taking a weight-loss drug was "cheating" rather than taking personal responsibility.
---
[32:28](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1948s) The Science of Dieting and Set Point Theory
To investigate whether traditional dieting is a viable long-term solution for most people, Hari interviewed Professor Traci Mann at the University of Minnesota in a Minneapolis cinnamon bun shop called Isles Bun & Coffee. Highlighting the ubiquitous nature of our obesogenic environment, the shop gave Hari a free 2,000-calorie cinnamon bun that sat on the table throughout their interview about dieting research.
When Professor Mann began evaluating diet studies in the year 2000, prevailing scientific consensus claimed diets were highly effective. However, her systematic meta-analysis of nearly 24,000 studies revealed a fundamental flaw: the overwhelming majority of studies only tracked dieters for three months. Participants exercised willpower, lost weight, and the studies ended, leaving the implicit assumption that the weight loss was permanent.
When Mann searched for long-term data, she found only 24 studies that tracked dieters over two years, and a handful that followed them for five years. The long-term picture was vastly different: - **Average Long-Term Weight Loss:** After two years, the average person on a traditional diet had retained a weight loss of only two pounds. - **Success Rate:** Only about 10% of people successfully lose significant amounts of weight on diets and keep it off long-term. - **The Paradox of Thermodynamics:** While the law of thermodynamics dictates that burning more calories than consumed leads to weight loss, human biological mechanisms actively fight this process over time.
To explain this paradox, researchers point to **Set Point Theory**. In the 1960s and 1970s, scientists hypothesized that the body regulates weight much like body temperature—using involuntary biological responses like shivering or sweating to keep internal conditions in a tight, fixed range. Though the sudden spike in global obesity in the late 1970s initially appeared to disprove the idea of a fixed weight set point, researchers like Dr. Michael Lowe at Drexel University discovered that **a person's set point rises as they gain weight**.
When a person gains significant weight, their body adopts that higher level as its new baseline and aggressively defends it. If they try to lose weight, their body responds defensively: - **Metabolic Slowing:** Metabolism slows dramatically to conserve energy. - **Increased Cravings:** Cravings for sweet and salty foods intensify. - **Decreased Energy:** Physical energy drops to disincentivize calorie expenditure.
From an evolutionary standpoint, this mechanism protected early humans against famine. In an environment where food scarcity was a constant threat, the body evolved to hold onto stored fat at all costs ("Timothy Chalamet dies in week one of a famine, while John Candy is the last man standing"). Because human evolution never prepared us for a world of hyper-abundant, low-cost calories, dieters are fighting an uphill battle against their own biology. Hari notes that GLP-1 drugs may work primarily by lowering this biological set point, preventing the body's defensive starving responses from kicking in.
---
[40:01](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2401s) Emotional Numbness and Eating for Comfort
Shifting to the psychological impacts of GLP-1 medications, Hari describes his own personal experience on the drug. Having lost three stone (42 lbs) over the course of a year in a steady downward trajectory, he noticed a strange emotional dissonance. While watching his pregnant friend Danielle expand as he shrank, he realized that despite getting the physical outcome he wanted, he felt emotionally dulled and flat rather than overjoyed.
Hari explains that science identifies five distinct reasons why human beings eat. While he previously assumed sustenance was the primary driver, his drastically reduced appetite made him examine the other roles food plays in daily life:
1. **Sustenance:** Fueling basic physiological needs. 2. **Pleasure:** Enjoying taste and culinary experiences. 3. **Comfort and Emotional Regulation:** Soothing stress, grief, or anxiety through food.
To illustrate how deeply embedded comfort eating is in human behavior, Hari highlights data showing massive spikes in junk food orders following stressful societal events—such as pizza and fried chicken orders soaring after 9/11, or taco orders spiking on food delivery apps in blue states on the night of the 2016 U.S. presidential election. On an individual level, losing a job drastically increases a person's risk of gaining weight due to emotional eating.
GLP-1 drugs abruptly strip away the ability to comfort eat, leaving individuals without their primary coping mechanism.
---
[42:41](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2561s) Lessons from Bariatric Surgery and Addiction Transfer
To understand the long-term psychological implications of suppressing appetite biologically, Hari points to bariatric (gastric band or stomach stapling) surgery as the closest historical equivalent. The physical health benefits of reversing severe obesity through surgery are massive:
- **Heart Attack Mortality:** 56% reduction over seven years. - **Cancer Mortality:** 60% reduction over seven years. - **Diabetes-Related Mortality:** 92% reduction over seven years. - **All-Cause Mortality:** 40% overall reduction over seven years.
However, the psychological fallout of abruptly eliminating food as a coping mechanism can be severe. - **Psychiatric Care:** 17% of bariatric surgery patients require inpatient psychiatric treatment post-surgery due to severe depression or distress. - **Suicide Risk:** The rate of suicide nearly quadruples following bariatric surgery. - **Addiction Transfer:** Roughly 1 in 10 bariatric surgery patients develop a new substitute addiction—such as alcoholism, gambling, compulsive shopping, or drug abuse—to replace the psychological comfort once provided by food.
Hari shares the story of a woman named Robyn Moore, who weighed 303 pounds before turning to bariatric surgery after feeling like a "slave" to food. Her experience highlighted how deeply psychological eating is, demonstrating that when a person's primary method of self-soothing is removed without addressing the underlying emotional driver, the psychological distress often transfers into new behaviors.
<ElicitationsGroup message="Explore related topics from this podcast episode:"> <Elicitation label="Discuss the 12 key risks of GLP-1 drugs" query="What are the 12 significant risks of Ozempic and GLP-1 drugs mentioned by Johann Hari?"/> <Elicitation label="Examine the impact of GLP-1s on addictions" query="How do Ozempic and GLP-1 drugs affect other addictions like drinking and shopping?"/> </ElicitationsGroup>
[45:36](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2736s) Trauma and the Unmasking of Appetite Suppression
When the underlying psychological triggers that drive overeating are suddenly dismantled by GLP-1 medications, the emotional reality underneath can surface with jarring intensity. In a profound example, a woman who had been sexually abused as a child deliberately carried extreme weight as a psychological shield to protect herself from men. After shedding the weight, she experienced a rapid, severe shift into alcoholism, losing her job near the Toronto airport due to drinking on duty. While this kind of extreme substitute addiction won't happen to the majority of patients, these drugs fundamentally disrupt emotional defense mechanisms.
Author Johann Hari shares a deeply personal anecdote from his time in Las Vegas while writing a true-crime book. After a particularly grim day of investigating, he instinctively went on autopilot to a local KFC on West Sahara—jokingly described as "the grimmest KFC in the whole world"—and ordered his usual mountain of fried chicken. Sitting beneath a poster of Colonel Sanders, he realized with a shock that he literally could not eat it. Being suddenly stripped of comfort eating is a difficult psychological reality. As a friend of his who navigated cancer astutely observed: "It's not that the drug is causing this problem; the drug is making this problem visible to you, and now you can deal with that in other ways." The sheer complexity of these physical and psychological trade-offs is why anyone framing weight loss drugs purely as a flawless miracle or an absolute evil isn't leveling with the public.
- **Vegas Anecdote Location:** The KFC on West Sahara Avenue, Las Vegas. - **The Core Paradox:** The drugs don't invent psychological distress; they remove the food-based coping mechanism used to suppress it.
[48:33](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2913s) The Kaiser Permanente Obesity Study and the Susan Case
The link between childhood trauma and compulsive comfort eating is backed by stark clinical data. In the early 1980s, a physician named Dr. Vincent Felitti was approached by the major non-profit medical provider Kaiser Permanente in San Diego. Confronted by an unprecedented rise in obesity rates that resisted traditional diet and exercise plans, they handed Dr. Felitti a large sum of money for "blue skies research" to find a root cause. Dr. Felitti began working with 200 severely obese patients and designed a radical, highly medically supervised program where participants practically stopped eating entirely, receiving vitamin shots to prevent deficiencies like scurvy so their bodies would burn through existing fat stores.
At first, the results were staggering. A patient given the pseudonym Susan dropped from over 400 pounds down to 138 pounds, prompting her family to call the doctor to thank him for saving her life. However, the experiment took an unexpected turn when Susan suddenly cracked, binged obsessively, and rapidly regained the weight. When Dr. Felitti investigated what happened on the exact day she broke her fast, Susan admitted she had been at a bar where a man hit on her in a perfectly polite manner, which completely panicked her. When asked about the year she first began gaining weight at age ten, she revealed it was the exact year her grandfather began raping her. Dr. Felitti subsequently interviewed every participant in the program and discovered a staggering 60% of the women had experienced extreme weight gain in the direct aftermath of sexual abuse or assault, using weight as a subconscious defense mechanism because, as Susan put it, "overweight is overlooked."
- **Principal Researcher:** Dr. Vincent Felitti in San Diego (early 1980s). - **Sponsor:** Kaiser Permanente. - **Susan's Weight Loss:** From over 400 lbs down to 138 lbs before regaining it. - **Key Statistic:** 60% of the women in the study developed severe obesity following sexual abuse or assault.
[52:25](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3145s) Surviving the Obesogenic Environment
Modern society functions as an "obesogenic environment"—a landscape systematically designed to prime human beings for weight gain while making a healthy lifestyle expensive, rare, and deeply difficult to maintain. As Professor Michael L. noted to Hari, humanity has engineered an environment as perfectly optimized for obesity as possible. Ultra-processed foods undermine a person's natural satiety cues through seven distinct mechanisms detailed in Hari's book *Magic Pill*, causing individuals to consume an average of 500 extra calories every single day.
While confronting the massive corporate and political forces behind processed food can spark deep pessimism, public health history proves that rapid societal transformations are entirely possible. A prime historical parallel is the dramatic decline of tobacco use. In 1987, over half the British population smoked regularly, lit cigarettes were ubiquitous on planes, subways, and game shows, and doctors even smoked during medical examinations. Hari recalls being with his mother on the anniversary of the tragic 1987 King's Cross station fire in London—which killed over 50 people after a discarded cigarette ignited a wooden escalator. When his mother called it the worst day of her life, it wasn't because she knew a victim, but because it was the day they banned smoking on the Underground. Today, British smoking rates have plummeted to roughly 12% and continue to fall. This proof of change shows that public health landscapes can be radically reshaped, despite pushback from incredibly powerful industries.
- **Caloric Surplus:** Eating processed foods causes people to consume an average of 500 more calories per day. - **Historical Comparison:** In 1987, over 50% of the UK population smoked; today, it is down to roughly 12%. - **King's Cross Fire:** Occurred in 1987, claiming over 50 lives and prompting the subway smoking ban. - **Political Reality:** As author Rebecca Solnit noted, "politicians are weather vanes, and it's our job to be the weather."
[58:06](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3486s) The Japanese Anomaly: Getting Rich Without Getting Fat
The global conversation often treats widespread obesity as an inescapable consequence of national wealth—an inevitability that will supposedly force 40% to 50% of Western populations onto weight loss drugs within a few years. However, Japan stands as a powerful counterexample, proving a nation can become wealthy without becoming fat. Only 4.5% of Japanese citizens are obese, compared to 26% in Great Britain and a staggering 42.5% in the United States. When combining the statistics for those who are either overweight or obese, the numbers show that carrying excess weight has become the absolute norm in the West, whereas it remains rare in Japan.
``` +---------------+-------------------+ | Country | Obesity Rate (%) | +---------------+-------------------+ | Japan | 4.5% | | Great Britain | 26.0% | | United States | 42.5% | +---------------+-------------------+ ```
This health disparity is entirely environmental rather than genetic. When Japanese populations migrated to Hawaii in the late 19th century and settled for generations, they adopted local dietary habits and experienced a five-fold increase in obesity rates compared to their counterparts in Japan, matching the baseline of other Hawaiians. Historically, Japan's food culture was consciously overhauled by the government. As Cambridge University Professor of East Asian History Barack Kushner points out, in the 1920s the average Japanese citizen had a terribly deficient diet, eating fish or protein only once a week. The government intentionally revolutionized the national food culture to build a healthier, stronger population. To observe the modern legacy of this systemic design, Hari visited the Kōchi School—an institution for children aged 5 to 18—where the day begins with all the children walking to school entirely on their own.
- **Migration Data Point:** Japanese-Americans in Hawaii are five times more likely to be obese than citizens living in Japan. - **Historical Context:** In the 1920s, the Japanese government deliberately transformed food culture away from a historically poor, low-protein diet to improve conscript health. - **Fieldwork Site:** The Kōchi School in Japan, serving students from ages 5 to 18.
[01:00:47](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3647s) Cultivating a Culture of Food in Japan
Johann Hari details his visit to a Japanese school of 1,000 children, where he was struck by the complete absence of childhood obesity. Starting at age five, Japanese children walk to and from school independently, building physical activity into their daily routine. Upon entering the school, Hari met Harumi Tate, a professional nutritionist. By law, every Japanese school employs a dedicated nutritionist who undergoes three years of specialized study on top of standard teacher training. Processed foods and packed lunches are strictly prohibited; every single meal is prepared fresh from scratch daily while doubling as a practical educational tool about healthy eating.
Children are taught fundamental cultural and nutritional principles, such as *hara hachi bu*—eating until one is only 80% full, allowing time for satiety signals to reach the brain. Meals typically consist of five small portions—such as white fish, miso soup, and sashimi—which promotes gut health through variety and naturally slows down the pace of eating. To demonstrate nutritional balance, the nutritionist holds up color-coded ropes to the class: a red rope representing calcium for strong bones, another for carbohydrates that supply energy, and then ties them together to visually represent a complete, balanced meal.
Hari shares a humorous moment from his tour when he asked students about their favorite foods. Expecting typical kids' answers, he was shocked when they answered "broccoli," "seaweed," and "white rice." Suspecting they were trolling him, he asked his translator, who looked genuinely puzzled and explained that Japanese children are simply raised to like healthy foods. When Hari showed the students photographs of typical British school lunches on his phone, they reacted with horror—as if viewing an "ISIS beheading video"—gasping in disbelief and asking, "Where's the salad?"
- In Japan, children walk to and from school on their own starting from age five. - Every school nutritionist completes 3 years of post-teacher training to design scratch-cooked, non-processed meals. - Japanese meals feature 5 small, varied portions consumed sequentially to slow down digestion and support gut health. - Cultural norm: *Hara hachi bu* (eating until 80% full).
---
[01:04:55](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3895s) Purchasing Ozempic, Novo Nordisk, and Eating Disorder Risks
Transitioning back to the Western landscape, Hari examines the massive craze surrounding Ozempic pens, manufactured by the Danish pharmaceutical giant Novo Nordisk. Driven by the viral demand for these weight-loss medications, Novo Nordisk has rapidly transformed into the most valuable company in Europe, fueling a significant portion of Denmark's recent economic growth. Alongside Eli Lilly, the market for GLP-1 drugs is projected to reach $200 billion by the end of the decade.
However, Hari raises grave concerns regarding how easily accessible these medications have become, particularly through online telehealth platforms. Although official guidelines require a minimum Body Mass Index (BMI) of 27 derived from fat mass rather than muscle mass, individuals can easily bypass these checks. On a video call, patients can simply lie about their measurements and receive the medication by mail two days later, or turn to illicit online channels for counterfeit versions.
This lack of strict physical oversight creates a severe danger for vulnerable populations, especially young women struggling with eating disorders. Describing Ozempic as "the most effective tool for self-starvation human beings have ever come up with," Hari relays warnings from eating disorder experts like Dr. Kimberly Dennis. She advocates that GLP-1 medications should strictly require in-person physician visits with doctors specifically trained to screen for eating disorders before issuing a prescription.
- **Novo Nordisk**: Danish pharmaceutical company behind Ozempic, now the most valuable company in Europe. - **Market Projection**: Estimated $200 billion global market for GLP-1 drugs by 2030. - **Prescription Criteria**: Officially intended for patients with a BMI of 27 or higher (based on fat mass). - **Online Telehealth Loophole**: Patients can lie about weight on Zoom calls to get pens delivered within 48 hours.
---
[01:07:43](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4063s) The Origins of GLP-1s and Cardiovascular Benefits
The underlying mechanism of Ozempic traces back to 1984, when researcher Dr. Daniel Drucker made a scientific breakthrough at Massachusetts General Hospital while studying the glucagon gene in the pancreas. By isolating GLP-1 from the end of the gene chain, Drucker discovered in laboratory dish tests that combining GLP-1 with insulin significantly boosted overall insulin production. Subsequent animal testing—conducted on rats by Professor Svetlana Mojsov and on pig pancreases by a research team in Copenhagen—confirmed these properties, laying the foundation for GLP-1 diabetes treatments. The appetite-suppressing effects of GLP-1 were later discovered independently at Hammersmith Hospital in London when human subjects injected with the hormone experienced a marked decrease in hunger.
Hari emphasizes that beyond cosmetic weight loss, these medications offer dramatic, life-saving cardiovascular benefits. For individuals starting with a BMI over 27, taking GLP-1 drugs over a five-year period reduces the overall risk of suffering a heart attack or stroke by 20%. Given that polling reveals 47% of Americans express an active willingness to take these medications, the public health implications are immense.
- **1984 Breakthrough**: Dr. Daniel Drucker isolated GLP-1 from the glucagon gene at Massachusetts General Hospital. - **Key Researchers**: Professor Svetlana Mojsov (rat trials) and Copenhagen scientists (pig pancreas trials). - **Appetite Discovery**: Identified during GLP-1 trials at Hammersmith Hospital in London. - **Cardiovascular Effect**: 20% reduction in heart attack and stroke risk over 5 years for individuals with a BMI over 27. - **Public Interest**: Polling indicates 47% of American adults actively want to take GLP-1 weight-loss drugs.
---
[01:10:15](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4215s) Thyroid Cancer Risks and Long-Term Safety Debates
Despite the enthusiasm, Hari outlines serious potential health risks highlighted in his research. He highlights the work of Professor Jean-Luc Faillie from the University Hospital of Montpellier, who was commissioned by the French medicines agency to conduct a rigorous safety investigation. While advocates like Dr. Drucker point out that diabetics have safely used GLP-1 medications for 18 years without catastrophic global side effects, Faillie sought to analyze long-term health registry data to check for specific conditions, notably thyroid cancer—which had previously shown elevated rates in rat studies.
Analyzing health databases of French diabetic patients who took GLP-1 drugs for three years between 2006 and 2015 compared to a matched control group, Professor Faillie uncovered a "sobering" finding: patients taking GLP-1s experienced a 50% to 75% relative increase in their risk of developing thyroid cancer. Hari clarifies that this does not mean 50% of users will develop cancer, but rather that an individual's baseline relative risk rises. While the European Medicines Agency (EMA) currently remains unconvinced by this data and some scientists dispute the findings, it represents a notable area of concern when millions of people worldwide are taking the drug.
- **French Health Study**: Led by Professor Jean-Luc Faillie at University Hospital of Montpellier for the French medicines agency. - **Data Range**: Tracked diabetics on GLP-1 drugs for 3 years between 2006 and 2015. - **Thyroid Cancer Risk**: Showed a 50% to 75% relative increase in thyroid cancer incidence among users. - **Baseline Context**: Approximately 1.2% of people get thyroid cancer in their lifetime, with an 84% survival rate.
---
[01:13:56](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4436s) "Ozempic Face" and the Agony of Pancreatitis
Addressing popular concerns, the conversation turns to the phenomenon known as "Ozempic Face"—a sunken, gaunt facial appearance caused by rapid weight loss. Hari jokes lightheartedly that he personally does not worry about it because his face is naturally so round that "babies always smile at me I think because they think I'm their King... like a baby that inexplicably got to walk around." He notes that Ozempic Face is not a physical health danger, but rather a cosmetic issue related to rapid facial fat loss.
A far more severe and painful side effect is pancreatitis, an acute and dangerous inflammation of the pancreas. Hari shares the story of Michelle Stonc, a woman from Myrtle Beach, North Carolina. Before starting the medication, her doctor mentioned pancreatitis as a rare side effect, to which she jokingly replied, "With my luck, I'll probably get it." Six weeks into her treatment—delighted with her initial weight loss—she traveled to Pittsburgh to visit her daughter and woke up in excruciating agony.
Describing the incident, Hari notes she experienced a burning pain radiating from below her breast to her back, accompanied by severe vomiting and distress. Her son-in-law called an ambulance believing she was dying. Upon arrival at the emergency room, doctors immediately evaluated her pancreas and asked two telling initial questions: whether she was a heavy drinker, and whether she was taking Ozempic.
- **"Ozempic Face"**: A cosmetic outcome of rapid weight loss leading to facial volume loss and a gaunt appearance. - **Pancreatitis Risk**: A rare but severe side effect involving acute inflammation of the pancreas. - **Case Example**: Michelle Stonc suffered severe abdominal pain, vomiting, and hospitalization 6 weeks after starting Ozempic.
[01:15:11](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4511s) Pancreatitis, Pronunciation, and the Next Generation of GLP-1 Drugs
While pancreatitis remains a rare outcome, studies show semaglutide increases the risk of developing it by a factor of nine. The clinical severity of this risk became apparent in a conversation with a patient named Michelle, who described the excruciating agony of pancreatitis as vastly worse than childbirth, requiring fentanyl for pain relief. Beyond acute medical emergencies, everyday confusion surrounds the drug itself, starting with its basic pronunciation. Johann Hari clarifies that while many instinctively pronounce the generic compound "sem-a-GLOO-tide," scientists standardly pronounce it "se-MAG-lu-tide."
Semaglutide serves as the active ingredient behind both Ozempic (marketed for diabetes) and Wegovy (marketed for obesity), both manufactured in the exact same facility by Novo Nordisk. However, semaglutide represents only the early stages of a massive pharmacological wave. Newer compounds are rapidly advancing through clinical trials: * **Mounjaro (tirzepatide):** Developed by Eli Lilly, it targets both GLP-1 and a second gut hormone, GIP, driving an average body weight loss of 21% compared to semaglutide's 15%. * **"Triple G" (retatrutide):** Activates three distinct gut hormones, achieving an unprecedented 24.2% average weight loss in trials.
Leading obesity experts view this transition as a monumental watershed moment. South African psychiatrist Carell le Roux compares humanity's current progress to a baby suddenly standing up and walking after months of crawling. Epidemiologist Tim Spector likened the discovery to finding the "Holy Grail" of weight loss, while researcher Robert Kushner described it as cracking open a treasure chest to reveal gut hormones as the central controllers of human body weight.
* **Pancreatitis Risk:** 9x increase in baseline risk on semaglutide, causing severe abdominal pain that often requires hospital-administered opioids. * **Gut Hormone Targets:** Scientists estimate there are up to 37 distinct gut hormones involved in appetite regulation, opening the door for dozens of upcoming drug variations.
---
[01:18:08](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4688s) The Unspoken Side Effect: Muscle Loss and Sarcopenia
A major, under-discussed downside of rapid weight loss on GLP-1 receptor agonists is significant muscle mass loss. When a person loses massive amounts of weight rapidly through caloric restriction or medication, the body naturally sheds both fat and lean muscle tissue. In clinical data, some individuals lose up to 20% to 30% of their total lean muscle mass after starting semaglutide.
The long-term public health consequence of this side effect is a potential "time bomb" of frailty, particularly for people using the drug for aesthetic reasons who were not obese to begin with. Human muscle mass naturally declines every year past the age of 30. Accelerating that loss through GLP-1 drugs significantly heightens the risk of sarcopenia—derived from the Greek for "poverty of the flesh"—in later life. Sarcopenia leaves older adults unable to navigate stairs, severely increases fall risks, and drastically raises mortality rates following physical trauma.
* **Baseline Loss:** Individuals typically shed significant muscle mass along with fat during rapid weight loss unless mitigated by targeted resistance training and high protein intake. * **Personal Anecdote:** Hari notes that during his own time on the medication, his body fat percentage dropped from 33% to 22% without a noticeable drop in muscle mass, though he jokingly attributes this to having virtually no muscle to lose initially.
---
[01:20:36](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4836s) Mental Health, Suicidality, and Psychological Disillusionment
Reports linking GLP-1 medications to increased feelings of depression, anxiety, and suicidality have triggered widespread scientific debate. Disentangling whether the drug directly alters brain chemistry or triggers psychological crises remains complex, as baseline mental health struggles occur across all populations over time.
Scientists evaluating these psychological risks point to two primary drivers: 1. **Dampening of Reward Pathways:** By suppressing dopamine responses in the brain's reward centers, the drug can inadvertently strip away the emotional comfort and pleasure individuals historically derived from food or other soothing behaviors. 2. **The "Anomalous Expectation" Crisis:** As Dr. Carell le Roux points out, many individuals who spent decades struggling with obesity believe their weight is the sole barrier to their happiness. When the weight comes off but their underlying life stressors, unhappy marriages, or unsatisfying careers remain unchanged, the severe emotional anticlimax can induce a profound mental health crisis.
> "A lot of people who are overweight for a long time say... 'The reason my life is [terrible] is because I'm overweight. If I finally lose weight, my life will be good.' And then they lose weight and they've still got the same hassle husband, and they've still got the same job they don't like, and they suddenly go into this crisis." — **Carell le Roux**
---
[01:22:50](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4970s) The Horrific History of Diet Drugs: DNP, Amphetamines, and Jaw Wiring
To understand the current caution around GLP-1 medications, one must examine the dark, historical pattern of weight loss interventions where early enthusiasm eventually gave way to catastrophic safety failures. Modern anti-obesity pharmacology began with 2,4-Dinitrophenol (DNP) during World War I, after French munitions workers handling explosive powders experienced dramatic weight loss. Stanford researchers subsequently commercialized it in 1934 as "Alpha-Dinitrophenol" or "Redusols," attracting over 100,000 users. The drug hyper-accelerated metabolism, but high doses caused severe cataracts, blindness, and lethal hyperthermia—literally cooking users' bodies from the inside out before it was reclassified as a pesticide.
Following WWII, pharmaceutical companies turned to amphetamines after military radar operators given the stimulant to stay alert showed marked appetite suppression. By 1970, amphetamine prescriptions for weight loss accounted for an astonishing 8% of all prescriptions written in the United States. However, patients rapidly developed tolerance, requiring escalating doses that triggered severe sleep deprivation, psychological dependence, and full-blown psychosis.
As medical authorities pulled back on amphetamines, extreme surgical interventions emerged, such as jaw wiring. This invasive procedure physically prevented solid food intake, but carried a horrifying fatal risk: if a patient vomited while their jaw was wired shut, they faced immediate asphyxiation and death.
* **DNP (1930s):** Industrial explosive powder turned diet pill; caused fatal body overheating, blindness, and extreme cellular toxicity. * **Amphetamines (1950s–1970s):** Marketed heavily to women ("Mother's Little Helper"); caused severe addiction, psychiatric crises, and tolerance. * **Jaw Wiring:** Physical restriction mechanism abandoned due to the high risk of fatal choking during vomiting.
---
[01:25:28](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5128s) The Fen-Phen Scandal and the Threat of "Unknown Unknowns"
The most glaring modern cautionary tale prior to GLP-1s was Fen-Phen, a combination of fenfluramine (an appetite suppressant) and phentermine (an amphetamine derivative). Surging to popularity in the mid-1990s, the combination was lauded on the cover of *Time* magazine as a miracle cure, generating over 18 million prescriptions annually in the U.S. alone.
The phenomenon collapsed when primary care physicians in Fargo, North Dakota, identified severe heart and lung damage in patients taking the cocktail. Fen-Phen caused primary pulmonary hypertension—a fatal contraction of lung blood vessels—and ruined heart valves. A prominent case involved Mary Linnen, a 28-year-old woman in Massachusetts who took Fen-Phen to lose weight for her wedding, developed irreversible pulmonary hypertension within weeks, required continuous oxygen therapy, and died shortly thereafter. The resulting legal liability led to a landmark $12 billion settlement by American Home Products, the largest pharmaceutical payout in history at the time.
While GLP-1 drugs possess a far broader body of clinical evidence than Fen-Phen (which was initially brought to market based on a single study of just 120 people), top researchers emphasize that long-term safety profiles remain incomplete. Dr. Greg Stanwood of Florida State University highlights the danger of "unknown unknowns"—unforeseen side effects that only surface after millions of people use a drug over decades. As an analogy, antipsychotic medications introduced in the 1950s were considered safe for decades before researchers discovered late-life neurological side effects in patients reaching their 70s and 80s. Similar unknown long-term risks, including potential birth defect risks identified in animal exposure studies, make current widespread adoption an unprecedented real-world experiment.
* **Fen-Phen Peak:** 18 million prescriptions annually before being pulled from the market in 1997. * **Legal Settlement:** $12 billion paid out to victims suffering from valve disease and pulmonary hypertension. * **Clinical Trial Baseline:** Fen-Phen had been evaluated in only 120 patients prior to widespread commercial release, whereas GLP-1s have undergone vastly larger clinical trials.
[01:29:08](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5348s) The "Unknown Unknowns" and the Brutal Reality of Obesity
Johann Hari addresses the terrifying potential of hidden, long-term risks associated with new brain-acting medications. Drawing a parallel to early antipsychotic prescriptions—where patients only discovered decades later that the drugs significantly increased their risk of Alzheimer’s disease and dementia—he warns that GLP-1 receptor agonists also carry "unknown unknowns." Because these drugs act heavily on core brain regions involved in memory, taste processing, and gut motility, unknown side effects could eventually surface. However, Hari argues that these potential future risks must be weighed against the definitive, catastrophic harms of chronic obesity.
Quoting Dr. Shauna Levy of the Tulane University School of Medicine, Hari emphasizes: "We don't know the long-term risks of these drugs; we do know the long-term risks of obesity, and they are horrific." He candidly admits his own past ignorance regarding conditions like diabetes, which he once assumed was easily managed with routine insulin injections. In reality, contracting diabetes strips an average of 15 years off a person's life expectancy and remains the single largest cause of preventable blindness in Britain and lower-extremity amputations in the United States—causing more limb losses annually than gunshot wounds. Hari recounts a stark declaration from his friend Dr. Max Pemberton: "If you gave me a choice between getting diabetes or becoming HIV-positive, I would choose HIV every time," because modern HIV treatments allow a normal life expectancy, whereas diabetes triggers widespread, irreversible organ damage.
* **Family History & Personal Choice:** Hari highlights that individual health contexts matter immensely; those with a family history of thyroid cancer or severe muscle loss concerns should avoid these medications. For himself, given his family's history of men dying young from heart attacks, he chose the calculated risk of taking Ozempic over remaining obese. * **The Fen-Phen Parallel:** While he considers a major safety failure unlikely, Hari cautions that a modern "Fen-Phen scenario"—where a wildly popular diet drug is later pulled due to severe heart valve damage—cannot be completely ruled out.
---
[01:32:26](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5546s) The "No Free Lunch" Philosophy and Systemic Economic Shocks
Steven Bartlett challenges the framing of weight-loss drugs by offering his own perspective formed through interviewing hundreds of health, psychology, and medical experts. He expresses a deep-seated belief that "there's no such thing as a free lunch in life" and compares medical interventions to the laws of physics: energy cannot be destroyed, only moved. When a pharmaceutical promises a shortcut, Bartlett argues, it simply shifts the problem somewhere else—such as the psychological transfer of food addiction to other compulsive behaviors. He shares how he reacts with skepticism when friends praise "smart drugs" like Modafinil as flawless fixes: "History shows if you wait long enough, there's always a cost."
Hari acknowledges this philosophy, noting that while some drugs like statins offer clear, unambiguous net benefits despite lifelong dependence, weight-loss drugs represent a far more finely balanced dilemma. Reflecting on reactions to his book *Magic Pill*, Hari notes that readers formed wildly opposite conclusions—some felt inspired to start Ozempic immediately, while others believed taking it was pure madness. Beyond personal choices, Hari highlights how GLP-1 drugs are already triggering massive economic ripples across global markets, reshaping entire industries.
* **Rebound Weight Gain:** Research shows that within one year of discontinuing GLP-1 medications, patients typically regain roughly 70% of the weight they lost. * **Market Disruption:** Emily Field, an equity analyst at Barclays, compared the societal impact of Ozempic to the invention of the smartphone. * **Industry Fallout:** Krispy Kreme donut stock prices dropped; Nestlé CEO Mark Schneider voiced concern over declining ice cream sales; and Jefferies financial analysts projected US airlines will save millions in jet fuel costs due to lighter passenger loads. * **Healthcare Shifts:** Companies manufacturing hinges for hip and knee replacements have seen stock declines, as reducing obesity directly decreases joint degradation and joint replacement surgeries.
---
[01:38:21](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5901s) Sponsored Segment: WHOOP
Steven Bartlett takes a brief break to highlight Stress Awareness Month and share his personal strategies for stress management, primarily heavy gym workouts and tracking biometric data. He explains his use of the WHOOP wristband—a company in which he is both a sponsor partner and an investor—specifically calling out its real-time stress monitor feature. Built on neuroscientific research and structured breathing exercises, the feature helps users identify and actively mitigate physiological stress spikes. He directs listeners to `[join.whoop.com/CEO](https://join.whoop.com/CEO)` for a 30-day risk-free trial.
---
[01:39:21](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5961s) Will Everyone Be on a Weight-Loss Pill?
Returning to the conversation, Bartlett contemplates a future where sedentary lifestyles and ultra-processed food environments continue to drive rising obesity rates. He posits that once GLP-1 medications transition from costly weekly injections to affordable daily oral pills, the primary psychological and financial barriers will vanish. He envisions a dystopian divide: 50% of the population taking a cheap daily pill to stay lean, while the remaining 50% struggle helplessly against an obesogenic environment.
Hari responds by outlining two distinct dystopian futures alongside one cautious best-case scenario:
* **The Elite-Only Dystopia:** The current reality where wealthy individuals (like "The Real Housewives of New Jersey") access cutting-edge weight-loss treatments, while lower-income populations (like public school children) face skyrocketing rates of childhood diabetes. * **The Mass-Medication Dystopia:** Once key patents expire—such as semaglutide's patent in 2032—manufacturing costs drop to around $40 per month. Combined with pill formulations, vast portions of the global population could end up taking daily appetite suppressants indefinitely without fully understanding the multi-generational impacts. * **The Optimistic Awakening:** A scenario where the widespread adoption of weight-loss drugs acts as a societal wake-up call, prompting governments and public health bodies to aggressively reform food environments and emulate countries like Japan through strict institutional food regulation.
Bartlett points out that without heavy government interventions on school nutrition and food manufacturing, mass reliance on medication seems inevitable—especially given rising rates of body dysmorphia and anxiety among younger generations who feel overwhelmed by modern food environments.
[01:43:26](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=6206s) The Food System vs. Regulation: Lessons from Japan and Beyond
Johann Hari dispels the common misconception that taking GLP-1 medications allows someone to keep eating fast food while staying slim. In reality, the drug suppresses the desire for food like fried chicken and burgers altogether. Reflecting on his own experience, Hari notes that even his taste for junk food waned over time. This leads into a deeper discussion about how society ended up relying on pharmaceutical interventions for weight loss in the first place.
Hari expresses anger over the realization that mass weight-loss medication—including its growing use in children—could have been avoided if governments had regulated the ultra-processed food industry. He highlights success stories from around the world showing that structural food reform is entirely possible:
* **Mexico:** Implemented a sugar tax that successfully reduced sugar consumption. * **Minneapolis, USA:** Introduced programs prescribing healthy food to low-income populations. * **Finland:** Undertook a comprehensive transformation of its national food supply. * **United Kingdom:** Professor Graham MacGregor successfully lobbied the UK government and food companies to reduce salt levels in bread. Done without public outcry, this reform prevented an estimated 6,000 to 9,000 strokes annually in the UK.
Hari compares these initiatives to Japan's cultural and policy interventions. In 2008, following a minor uptick in weight gains, Japan enacted the **Metabo Law** to combat metabolic syndrome. Under this law, companies are required to measure employee waistlines annually; if weight increases overall, the company risks government fines. Visiting the Japanese company Tanita, Hari observed extreme workplace health tracking, including mandatory step counts, meal photo uploads, and group workplace aerobics. While admitting such intrusive measures would face severe backlash in Western countries, Hari emphasizes that Japan’s broader health policies yield remarkable outcomes: Japan holds the world's highest life expectancy and exceptionally high healthy life expectancy.
During his research in Ogimi, Okinawa—known as the oldest village on Earth, where 190 out of 215 households include a resident over 90—Hari met 102-year-old Matsu Fukuchi. She shared her vibrant daily routine of caring for her son, watching volleyball, and dancing in a traditional red kimono. Hari reflects on the stark contrast between her youth (born before radio came to Japan) and his interviewing her on an iPhone. He argues that this level of health and joy in old age is what true systemic food reform offers—a stark contrast to the current reality where millions die prematurely from obesity-related complications.
- **Ogimi Village, Okinawa:** 190 of 215 households contain someone over the age of 90. - **UK Salt Reform Impact:** Reduced annual stroke events by 6,000 to 9,000 without consumers noticing a taste difference. - **Corporate Accountability in Japan:** Companies face financial penalties under the Metabo Law if their workforce's average weight increases.
---
[01:50:46](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=6646s) Long-Term Risks, Tolerance, and Metabolism
Turning to the long-term reality of taking GLP-1 drugs, Hari candidly acknowledges that stopping the medication usually leads to weight regain. Clinical trials show that approximately 70% of individuals regain lost weight within one year of discontinuation. Unless someone maintains a strict regimen indefinitely, long-term weight maintenance on the drug remains a challenge.
The discussion shifts to open medical questions regarding tolerance and metabolic changes:
* **Drug Tolerance:** Experts remain divided. Diabetics on GLP-1s generally do not seem to build tolerance (as their required dosage for blood sugar control remains steady), yet many pharmacologists anticipate that tolerance for weight loss could eventually occur. South African psychiatrist Dr. Carel le Roux compares GLP-1 drugs to bariatric surgery: patients lose significant weight, experience a slight plateau or minor regain, and eventually level off. * **Metabolic Slowdown:** All forms of rapid weight loss slow down baseline metabolic rate. Hari expresses concern that long-term use—or abrupt withdrawal due to unforeseen side effects—could leave users with a permanently slowed metabolism and higher baseline body fat than when they started.
---
[01:53:59](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=6839s) Eating Disorders, Youth, and Hollywood's Secrets
The conversation turns to the societal risks surrounding GLP-1 adoption, particularly among young people and those vulnerable to eating disorders. Host Stephen Bartlett notes that since March 2020, eating disorder diagnoses (such as anorexia and bulimia) among teenage girls aged 13–16 surged by 42%, and by 32% among young women aged 17–19 (citing studies in *The Lancet* attributed largely to pandemic lockdown stress).
Hari warns that combining powerful appetite suppressants with eating disorder dynamics can lead to tragic consequences. He points to historical precedent: in the early 1990s, popular amphetamine-based diet drugs swept across America, triggering severe health crises among young women. Congressional hearings led by Ron Wyden (then an Ohio Congressman) documented tragic cases:
> "I'm hungry, I want to eat, but not yet, not yet." > — *Poem read during Congressional hearings by Tony Smith, whose daughter Noel died of a heart attack caused by extreme diet drug abuse.*
* **Jessica McDonald:** A ballet dancer in her early 20s who took amphetamine diet drugs until she passed out in order to maintain an extreme physical aesthetic. * **Noel Smith:** A young girl who became obsessed with fashion magazine standards, abused diet pills to starve herself, and ultimately died from a heart attack.
Hari shares a personal moment when his 18-year-old niece Erin complimented his weight loss over FaceTime, noting his defined jawline, before asking: *"Will you get me some Ozempic?"* Despite being at a completely healthy weight, she had internalized the cultural pressure. Hari realized that his own transformation sent an unintended message counter to everything he had tried to teach her about body image.
Finally, Hari and Bartlett address the sudden wave of rapid weight loss among public figures and celebrities. While many public figures attribute their dramatic transformations solely to new fitness regimes or diets, Hari strongly suggests that widespread off-label GLP-1 use is the driving factor, calling out the culture of secrecy surrounding celebrity weight loss.
Here is a detailed, faithful walkthrough covering the specified transcript segment.
---
[01:58:16](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7096s) Social Stigma, Judgment, and Obesity as a Cultural "Sin"
Johann Hari and host Steven Bartlett explore why the societal judgment around weight loss drugs like Ozempic is so fiercely gendered and moralized. Hari notes that women face far harsher public criticism than men for using these medications. He shares an observation from one of his editors, who told him that "only a man could write this" book because a female author would be "crucified" or "monstered" for addressing the topic. They discuss how high-profile figures like Oprah Winfrey face severe backlash when speaking publicly about weight loss.
Hari reflects on his own internal conflict while taking Ozempic, admitting that for a long time he felt like he was "cheating" or "sinning." He traces this feeling back to deeply ingrained cultural narratives that date as far back as Pope Gregory I in the 6th century, who established the seven deadly sins—including gluttony, which historically featured grotesque, shaming depictions of fat individuals. In Western culture, admired forms of weight loss follow a traditional Catholic pattern of sin, suffering, penance, and redemption. Society demands that individuals starve themselves or undergo humiliating, grueling exercises—much like the TV show *The Biggest Loser*—before being granted societal forgiveness.
``` Classic Pattern of Moralized Weight Loss: Sin (Obesity/Gluttony) ➔ Suffering & Penance (Extreme Starvation/Humiliation) ➔ Redemption ➔ Public Forgiveness ```
Hari points out the double standard by comparing GLP-1 agonists to cholesterol-lowering statins: no one taking statins for a heart condition feels as though they are "cheating." He explains that people who endure immense deprivation to stay thin often view GLP-1 users the way clean cyclists viewed Lance Armstrong. However, Hari argues that the true villain is not individuals seeking health solutions, but rather the ultra-processed food industry that engineered the obesogenic environment in the first place. Comparing modern society to a 1975 British beach—where almost everyone was naturally lean—highlights how rapidly the environment changed, forcing people to process overwhelming amounts of shame and public hostility.
- **Gender Disparity in Criticism:** Women bear a disproportionate burden of body judgment and public insults regarding weight and pharmaceutical interventions. - **Extreme Public Stigma:** According to data cited by Hari, 45% of women with a BMI over 35 face direct public insults every single day. - **Parasocial Relationships and Public Reactions:** Sudden transformations in public figures—such as Adele or Rebel Wilson—often trigger feelings of anger or betrayal from fans who relied on them as relatable icons, reflecting deep-seated emotional pain and societal shame surrounding body image.
> "There is a sin and there are people who are cheating, but it's not Oprah... it's the food industry that fucked all of us, that's why we're in that race."
---
[02:05:37](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7537s) Ozempic as an "Addiction Killer" and Animal Research
The discussion shifts to one of the most surprising and controversial discoveries regarding GLP-1 receptor agonists: their potential to suppress addictions beyond food cravings. Hari outlines pioneering research conducted on animals that indicates GLP-1 drugs directly impact the brain’s reward systems.
In Sweden, Professor Elisabeth Jerlhag at the University of Gothenburg conducted experiments with rats accustomed to heavy alcohol consumption. After administering semaglutide, researchers observed that the rats voluntarily reduced their alcohol intake by approximately 60%, with the heaviest drinkers experiencing the most drastic reduction. To test whether this was purely driven by caloric suppression, subsequent experiments evaluated non-caloric substances:
* **Heroin & Fentanyl:** Professor Patricia "Sue" Grigson at Penn State University tested rats addicted to opioids and recorded a **50% reduction** in self-administration following GLP-1 treatments. * **Cocaine:** Professor Gregg Stanwood at Florida State University observed a **50% reduction** in cocaine consumption in mice.
``` [ GLP-1 Agonist Administration ] │ ┌───────────────────┼───────────────────┐ ▼ ▼ ▼ Alcohol Intake Opioid Usage Cocaine Usage Reduced ~60% Reduced ~50% Reduced ~50% (Jerlhag Lab) (Grigson Lab) (Stanwood Lab) ```
Scientists refer to this phenomenon as **selective activity**—the drug appears to downgrade cravings for harmful, highly compulsive behaviors while leaving healthy functions intact. While full human clinical trials are ongoing, early anecdotal reports (such as a Canadian nurse named Tracy, whose compulsive shopping, skin-picking, and binge eating stopped after taking Ozempic) and preliminary small-scale human trials suggest promising results, particularly when combining GLP-1s with other treatments like nicotine patches for smoking cessation.
> "What we found is a drug that boosts self-control across the board... the animal research is mind-blowing and really is highly, highly exciting."
---
[02:10:25](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7825s) Personal Results, Dose Escalation, and Oprah's Journey
Hari shares his personal experience taking semaglutide, detailing his physical transformation over a single year. Starting with a body fat percentage of 33%—which his trainer Josh noted with a wince—Hari reduced his body fat down to 22%, losing three stone (42 lbs) in total.
He explains the standard dose escalation protocol, which begins at 0.25 mg specifically to help patients acclimate to side effects. Nausea is by far the most common reaction; while Hari's nausea eventually subsided completely, others experience severe distress. He quotes obesity researcher Carel le Roux, who bluntly states that in pharmacology, "there are two kinds of drugs: there are drugs that have side effects, and there are drugs that don't work."
The conversation concludes with a discussion of Oprah Winfrey's public journey with weight loss drugs. Having endured decades of extreme dieting—famously wheeling out a wagon containing 67 pounds of animal fat on her talk show after a liquid diet—Oprah spoke openly in interviews with *People* magazine and an ABC television special about how GLP-1 medications provided relief from a lifetime of relentless food noise and constant struggle.
- **Weight Loss Data:** Hari dropped 3 stone (42 lbs) over 12 months, reducing body fat from 33% to 22%. - **Dose Protocol:** Standard initiation begins at 0.25 mg to manage gastrointestinal side effects. - **Oprah Winfrey's Public Legacy:** Celebrated as a major turning point in reframing obesity as a chronic biological condition rather than a personal moral failure.
> "When it comes to nausea, you've got to level with people: there are two kinds of drugs—there are drugs that have side effects and there are drugs that don't work."
[02:12:51](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7971s) Complex Truths: The Oprah Example and the Three Forms of Magic
Johann Hari highlights that evaluating obesity treatments like Ozempic requires navigating profound personal and medical complexities. Mentioning high-profile cases like Oprah Winfrey—who openly disclosed her knee surgery and serious health concerns—Hari explains how transformational weight loss has yielded life-changing health benefits for many individuals. Despite the legitimate concerns and potential side effects associated with GLP-1 receptor agonists, Hari finds it impossible to argue against the choices of people who have experienced a dramatic improvement in their health and quality of life.
To capture the nuances of these treatments, Hari explains why he titled his book *Magic Pill*. He breaks down the concept of "magic" into three distinct interpretations: * **A Miracle Solution:** The drug appears to solve a massive, deeply entrenched problem so swiftly and effectively that it feels like a genuine miracle. * **An Illusion:** Like a magician's sleight of hand, it provides the appearance of fixing a problem without addressing the underlying root causes, potentially setting up future complications. * **A Cautionary Tale:** Akin to classic folklore or *Fantasia*, where a wish granted by a genie comes with unforeseen consequences, leaving humanity to deal with a solution that spirals in unpredictable directions.
- Oprah Winfrey chose to take GLP-1 medications following knee surgery and pressing health worries. - Jeff Parker in San Francisco is cited as another individual who experienced life-changing benefits from weight loss drugs.
---
[02:15:03](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8103s) Will Ozempic Lead to a Decline in Physical Exercise?
Stephen Bartlett shares a candid moment of internal debate: while staring at the Ozempic pen, he pondered whether using such a drug to eliminate belly fat might tempt him—and society at large—to skip the gym altogether. While an injection might yield aesthetic results, it forfeits the crucial mental health benefits, brain-derived neurotrophic boosts, and cardiovascular rewards gained through active exercise. Hari agrees wholeheartedly, warning that widespread adoption of these medications will likely lead to reduced physical activity, worsening existing sedentary lifestyle trends.
``` Exercise Benefits vs. Weight Loss ┌─────────────────────────────────────────────────────────┐ │ Exercise (270 hrs/yr) ──► +3 Years Longevity │ │ (Mental Health & Anti-Aging) │ ├─────────────────────────────────────────────────────────┤ │ Weight Loss Injections ──► Rapid Fat Reduction │ │ (No Cardiovascular/Brain Up)│ └─────────────────────────────────────────────────────────┘ ```
Hari outlines clear guidance regarding who should and should not consider these medications: * **BMI Under 25 (Non-Overweight/Obese):** "If you are not overweight or obese, you definitely shouldn't take these drugs." Taking them solely for aesthetic thinness incurs all the physical risks with none of the health benefits. * **BMI Over 35:** For individuals with a BMI over 35 (and no family history of medullary thyroid cancer or plans for immediate pregnancy), the risk-benefit balance heavily favors taking the medication if traditional dieting has failed. * **BMI Between 27 and 35:** This threshold requires a carefully weighed personal risk-benefit assessment, where reasonable individuals will arrive at different conclusions.
- Exercising for approximately 270 hours a year adds an average of three years to a person's lifespan, completely independent of weight loss. - Elise Loehnen, former Chief Content Officer at Goop, noted that social dining culture in Los Angeles has shifted dramatically due to widespread appetite suppression, remarking that "dieting is out, elimination is in." - A lighthearted social observation: if a celebrity loses significant weight through grueling gym sessions and diet changes today, public skepticism is so high that virtually no one will believe they did it without Ozempic.
---
[02:18:58](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8338s) Shortages and the Ethical Dilemma for Diabetics
The explosive demand for Ozempic among non-diabetics seeking weight loss has caused severe global supply shortages, leaving Type 2 diabetics unable to access critical medication. Hari shares the story of Zami Jalil, a 41-year-old musician who could not obtain the Ozempic necessary to manage his Type 2 diabetes due to market scarcity. Forcing diabetics off GLP-1 medications and back onto early insulin therapy carries grave long-term health risks.
Hari expresses personal remorse for taking the drug given his family history of heart disease, acknowledging that his own access contributed to the broader systemic shortage. He argues that governments should have managed distribution similarly to the COVID-19 vaccine rollout by establishing a strict triaged rationing system:
1. **Top Priority:** Diabetics and severely obese individuals with critical medical needs. 2. **Moderate Priority:** Individuals with moderate obesity or elevated genetic risks (e.g., family history of heart disease). 3. **Lowest Priority:** Mildly overweight individuals seeking modest weight reduction.
---
[02:20:42](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8442s) Reflection on Authorship and Storytelling
Stephen Bartlett takes a moment to express deep gratitude to Johann Hari, recalling their early history when Hari agreed to appear on *The Diary Of A CEO* back when Bartlett recorded in his London flat with a tiny audience and poor audio quality. Bartlett praises Hari's ability to tackle controversial subjects with exceptional nuance, avoiding dogmatism while framing complex trade-offs so readers can make informed personal choices. He cites Hari's narrative style in *Magic Pill* as a profound influence on his own writing.
- Johann Hari's book *Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs* was scheduled for publication on May 2, 2024.
---
[02:23:10](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8590s) The Last Guest Question: Why Should Humanity Exist?
Following the podcast's tradition, Hari answers a closing question left by the previous guest: *"Why should humanity continue to exist?"* To answer, Hari draws on his 13 years of research into a series of events in Las Vegas, focusing on two men—Rob Banghart (known in the tunnels as "Hobo Santa") and Paul Veen-O—who lived in the extensive storm drainage tunnels beneath the city before turning their lives around.
Hari recounts a harrowing incident from 2017 when Rob was attacked by rival dealers who split his skull open with an axe and left him on railway tracks to be run over by a train. Miraculously surviving, Rob turned his life around and joined *Shine a Light*, a non-profit run by Paul to deliver aid, flashlights, and practical support to people still living in the underground tunnels.
A few years later, while visiting the tunnels after a mutual friend named Picket died of an overdose, Rob insisted on delivering food supplies to a group of men that other residents warned him to avoid. When Hari later asked why Rob helped them, Rob revealed that those very men were the ones who had struck him with the axe and tried to kill him. "Because they're human beings and they're suffering and they need help," Rob explained. For Hari, this radical capacity for forgiveness and empathy demonstrates the ultimate value of human existence.
> "Why did you go and help them?" > "Because they're human beings and they're suffering and they need help."
[02:26:47](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8807s) Why Human Beings Should Continue to Exist
Johann Hari reflects on extraordinary individuals like Rob and Paul, who dedicate their lives every single day to helping those left behind by society. They earn no money from this work and live lives without material luxury, yet when asked why they make such personal sacrifices, their response is disarmingly simple: "because it's the right thing to do." For Hari, this unpretentious, selfless commitment captures the absolute best of human nature.
When considering the fundamental question of why humanity deserves to continue existing, Hari observes that while one could point to abstract answers like philosophy or art, the true answer is found in real-world compassion. Meeting people like Rob and Paul offers direct proof of human worth and moral goodness. The interview concludes on this quiet, emotional note as Hari thanks Steven Bartlett and wraps up their conversation.
## Notable quotes > [00:00](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=0s) the most effective tool for self-starvation human beings have ever come up with. — Johann Hari
> [15:43](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=943s) Who are you and what have you done with Johann? — Johann Hari's godson
> [26:17](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=1577s) When I had cancer, we know there is something in the environment that is triggering breast cancer in women... But you didn't say to me when I got breast cancer, 'Well, fuck me, all this environmental problem has caused this breast cancer and now you want to inject yourself with another poison, chemotherapy, in order to deal with it?' No, you said, 'Okay, we've got an environmental problem, obviously that environmental problem needs to be dealt with, but you've got to stay alive or you can't deal with it.' — Judy
> [45:36](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=2736s) It's not that the drug is causing this problem; the drug is making this problem visible to you, and now you can deal with that in other ways. — Johann Hari's friend
> [52:25](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=3145s) politicians are weather vanes, and it's our job to be the weather. — Rebecca Solnit
> [01:20:36](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=4836s) A lot of people who are overweight for a long time say... 'The reason my life is [terrible] is because I'm overweight. If I finally lose weight, my life will be good.' And then they lose weight and they've still got the same hassle husband, and they've still got the same job they don't like, and they suddenly go into this crisis. — Carell le Roux
> [01:29:08](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5348s) We don't know the long-term risks of these drugs; we do know the long-term risks of obesity, and they are horrific. — Shauna Levy
> [01:29:08](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=5348s) If you gave me a choice between getting diabetes or becoming HIV-positive, I would choose HIV every time — Max Pemberton
> [01:53:59](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=6839s) Will you get me some Ozempic? — Erin
> [01:58:16](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7096s) There is a sin and there are people who are cheating, but it's not Oprah... it's the food industry that fucked all of us, that's why we're in that race. — Johann Hari
> [02:05:37](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7537s) What we found is a drug that boosts self-control across the board... the animal research is mind-blowing and really is highly, highly exciting. — Johann Hari
> [02:10:25](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=7825s) When it comes to nausea, you've got to level with people: there are two kinds of drugs—there are drugs that have side effects and there are drugs that don't work. — Carel le Roux
> [02:15:03](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8103s) If you are not overweight or obese, you definitely shouldn't take these drugs. — Johann Hari
> [02:15:03](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8103s) dieting is out, elimination is in. — Elise Loehnen
> [02:23:10](https://www.youtube.com/watch?v=0YMnHNIuK3M&t=8590s) Because they're human beings and they're suffering and they need help. — Rob Banghart
## Mentioned Johann Hari, Steven Bartlett, The Diary Of A CEO, Ozempic, Wegovy, Mounjaro, retatrutide, tirzepatide, Jens Juul Holst, Jay Rayner, Dr. Carel le Roux, Dr. Adalia G., Professor Paul Kenny, Professor Michael Lowe, Jeff Parker, Professor Traci Mann, Isles Bun & Coffee, Robyn Moore, Dr. Vincent Felitti, Kaiser Permanente, Rebecca Solnit, Barack Kushner, Kōchi School, Novo Nordisk, Eli Lilly, Dr. Kimberly Dennis, Dr. Daniel Drucker, Professor Svetlana Mojsov, Hammersmith Hospital, Professor Jean-Luc Faillie, University Hospital of Montpellier, European Medicines Agency (EMA), Michelle Stonc, Tim Spector, Robert Kushner, Dr. Greg Stanwood, Mary Linnen, American Home Products, Dr. Shauna Levy, Dr. Max Pemberton, Barclays, Emily Field, Krispy Kreme, Nestlé, Mark Schneider, Jefferies, WHOOP, The Real Housewives of New Jersey, Professor Graham MacGregor, Tanita, Matsu Fukuchi, Ron Wyden, Jessica McDonald, Noel Smith, Tony Smith, Erin, Oprah Winfrey, Pope Gregory I, Adele, Rebel Wilson, Lance Armstrong, Elisabeth Jerlhag, University of Gothenburg, Patricia 'Sue' Grigson, Penn State University, Gregg Stanwood, Florida State University, Tracy, Josh, People magazine, ABC, Goop, Elise Loehnen, Zami Jalil, Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs, Rob Banghart, Paul Veen-O, Hobo Santa, Picket, Shine a Light, The Lancet, The Biggest Loser
[Source](https://www.youtube.com/watch?v=0YMnHNIuK3M)